Rakovina Therapeutics

Press Releases & News Coverage

Press Releases

Sept 10, 2026: Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

Aug 31, 2026: Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

Aug 19, 2026: Rakovina Therapeutics Announces Results from 2026 Annual General Meeting

Aug 12, 2026: Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement

Jul 15, 2026: Rakovina Therapeutics Announces $1.5 Million Private Placement

Jun 1, 2026: Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Apr 30, 2026: Rakovina Therapeutics Announces 2025 Financial Results and Provides Corporate Update

Apr 22, 2026: Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

Mar 23, 2026: Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum

Mar 12, 2026: Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

Mar 5, 2026: Rakovina Therapeutics Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

Feb 20, 2026: Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

Feb 4, 2026: Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

Jan 27, 2026: Rakovina Therapeutics Announces Corporate Update Including up to $1.6 Million in New Financing, Leadership Appointments and Debt Restructuring

Jan 8, 2026: Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

Dec 17, 2025: Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

Dec 10, 2025: Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

Dec 1, 2025: Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update

Nov 28, 2025: Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

Nov 24, 2025: Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting

Nov 24, 2025: Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Nov 18, 2025: Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit

Nov 10, 2025: Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

Oct 27, 2025: Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference

Oct 16, 2025: Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-
NCI-EORTC International Conference     

Sept 4, 2025: Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025: Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

Aug 26, 2025: Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

Aug 12, 2025: Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging Al-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

July 30, 2025: Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

July 29, 2025: Rakovina Therapeutics Announces Stock Option Grants

July 24, 2025: Rakovina Therapeutics Announces Warrant Exercise Incentive Program

July 23, 2025: Rakovina Therapeutics KT-5000Al Program Yields Potent ATR Inhibitor Hits in Early Screening

July 15, 2025: Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access

July 11, 2025: Rakovina Therapeutics Congratulates Partner – Variational Al for Winning Life Sciences BC’s 2025 Emerging Biotech Company of the Year Award

July 10, 2025: Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in Al-Enabled Oncology Drug Development

June 30, 2025: Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

June 30, 2025: Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025

June 25, 2025: Rakovina Therapeutics Announces Results from 2025 Annual General Meeting

June 20, 2025: Rakovina Therapeutics Announces Share Consolidation Effective Date

June 12, 2025: Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

June 6, 2025: Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

June 2, 2025: Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides 
Corporate Update

May 28, 2025: Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

May 15, 2025: Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation

May 05, 2025: Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer

April 30, 2025: Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

April 29, 2025: Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherevok and David Kideckel

April 29, 2025: Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025 

April 22, 2025: Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery   t

March 25, 2025: Rakovina Therapeutics Unveils Preclinical Data at the AACR – World’s Premier Cancer Research Forum

March 12, 2025: Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Feb 26, 2025: Rakovina Therapeutics and Variational AI Strengthen Partnership

Feb 6, 2025: Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program 

Jan 30, 2025: Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange

Jan 29, 2025: Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference

Jan 22, 2025: Rakovina Therapeutics Comments On $500 Billion AI Infrastructure Investment and Its Implication on Healthcare Innovation

Jan 13, 2025: Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variation AI

Jan 6, 2025: Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation

Jan 3, 2025: Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week

Dec 19, 2024: Reflecting on 2024 Success and Building Momentum for a Transformative 2025

Dec 17, 2024: Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment ObligationsRakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Dec 13, 2024: Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Dec 3, 2024: Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

Dec 2, 2024: Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million

Nov 29, 2024: Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update

Nov 28, 2024: Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million

Nov 27, 2024: Rakovina Therapeutics Announces Private Placement Offering

Nov 25, 2024:  Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting

Nov 20, 2024: Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas

Oct 25, 2024: Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain

Oct 23, 2024: Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform

Sept 17, 2024: Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

Aug, 30, 2024: Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

July 26, 2024: Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement

July 22, 2024: Rakovina Therapeutics Provides Update on Previously Announced Private Placement

July 19, 2024: Rakovina Therapeutics Announces Second Upsizing of Private Placement

June 20, 2024: Rakovina Therapeutics Announces Oversubscribed Private Placement And Results From 2024 Annual General Meeting

May 30, 2024: Rakovina Therapeutics Announces 2024 Q1 Financial Results And Provides Corporate Update

May 24, 2024: Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

May 23, 2024: Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

May 08, 2024: Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

April 26, 2024: Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update

April 26, 2024: Consolidated financial statements

April 26, 2024: Management Discussion and Analysis

April 9, 2024: Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today

March 27, 2024: Rakovina Therapeutics Announces Strategic Pivot to AI

November 27, 2023: Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update

November 20, 2023: Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

August 29, 2023: Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update

August 29, 2023: Interim Condensed Consolidated Statements of Financial Position

August 29, 2023: Management Discussion and Analysis

June 28, 2023: Rakovina Therapeutics Announces Results from 2023 Annual General Meeting

May 30, 2023: Management Discussion and Analysis

May 30, 2023: Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update

May 29, 2023: Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing

May 1, 2023: Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing

April 20, 2023: Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

April 17, 2023: Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023

Mar 30, 2023: Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs 

Mar 22, 2023: Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies

Jan 26, 2023: Rakovina Therapeutics Announces Presentation at the 6th Annual DDRinhibitors Summit

Nov 23, 2022: Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

Nov 17, 2022: Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update

Nov 14, 2022: Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma

Oct 31, 2022: Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Sept 28, 2022: Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations

August 11, 2022: Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update

June 23, 2022: Rakovina Therapeutics Announces Results from Annual General Meeting

May 26, 2022: Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update 

May 11, 2022: Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas

April 27, 2022: Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

April 12, 2022: Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR)

March 30, 2022: Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

March 09, 2022: Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

February 21, 2022: Rakovina Therapeutics preventing cancer cells from making DNA repairs they need to survive

January 25, 2022: Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

January 06, 2022: Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

December 21, 2021: Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

November 23, 2021: Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 16, 2021: Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

November 11, 2021: Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference

October 21, 2021: Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference

October 12, 2021: Rakovina Therapeutics Presents at the 2021 AACRNCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 7, 2021: Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors

September 16, 2021: Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference 

September 9, 2021: Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference 

August 26, 2021: Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 17, 2021: Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

June 29, 2021: Rakovina Therapeutics Announces Results from Annual General Meeting

June 17, 2021: Rakovina Therapeutics to Present at at The Emerging Growth Conference on June 23, 2021

May 27, 2021: Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Corporate Update

April 29, 2021: Rakovina Therapeutics Inc. Announces Inaugural Scientific Advisory Board

April 8, 2021: Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors

April 5, 2021: Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors

April 1, 2021: Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol “RKV”

March 25, 2021: Rakovina Therapeutics Inc. (Formerly Vincero Capital Corp.) Announces Closing of Qualifying Transaction

March 19, 2021: Vincero Capital Corp. Announces Filing of Filing Statement in Connection with Qualifying Transaction

March 12, 2021:  Vincero Capital Corp. Receives Conditional Approval of TSX Venture Exchange for Qualifying Transaction with NewGen Therapeutics, Inc. and Announces Over-Subscribed Financing

November 10, 2020:  Vincero Capital Provides Update on Qualifying Transaction

Upcoming Presentations

Check back soon….